Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZKGZ009
- Development stage
- Preclinical
- Lead developer
- Lee's Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ZKGZ009 is an investigational drug candidate currently in the preclinical stage of development by Lee's Pharmaceutical, specifically through its subsidiary Zhaoke Pharmaceutical (Guangzhou). It is being developed for the treatment of psychiatric disorders. As a preclinical asset, specific pharmacological details regarding its molecular target, binding affinity, and precise mechanism of action have not been publicly disclosed in clinical registries or corporate pipeline summaries. The drug is part of Lee's Pharmaceutical's broader effort to expand its portfolio in the central nervous system (CNS) therapeutic area.
Beyond the preview
Go deeper on ZKGZ009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZKGZ009.